Main Industry
Health Care
Main Product/Service
1. Botanical Drug Active Substance Screening Platform
2. GACP Cultivation Philosophy and Plantation Planning
3. Botanical New Drug R&D: Alzheimer's Disease Drug (AD1)
2. GACP Cultivation Philosophy and Plantation Planning
3. Botanical New Drug R&D: Alzheimer's Disease Drug (AD1)
The content above was translated by Ai
Founded Year
2011
Unified Business No.
53437018
Status
Active
Number of Employees
0
Total Paid-in
Capital
303,111,510 (NT$)
Location of Company
Taiwan
, Taipei City
Company names, registration status, legal representatives, founding years, paid-in capital, registered addresses, and other details are sourced from business registration records maintained by Taiwan’s Administration of Commerce, Ministry of Economic Affairs. Exit status includes Emerging Stock Board listings, M&A, and IPOs. Information on overseas expansion is self-reported by startups.
Note 1: FINDIT compiles company information from public and other sources for reference and does not serve as a point of contact for the companies listed.
Note 2: Some company profiles and product/service descriptions are translated using AI and provided for reference only. In case of discrepancies or ambiguity, the original text prevails.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
B&V BIOPHARMA CO., LTD. is a company focusing on the research and development of botanical new drugs, with over 80% of its talent pool consisting of master's and doctoral degree holders. Currently, the company's core botanical new drug is for Alzheimer's disease. The company has commissioned Taiwan EPS Health Care Bio-tech Consulting Co., Ltd., a CRO (Contract Research Organization) under Japan's ITOCHU Group, to submit an IND (Investigational New Drug) application for Phase II clinical trials in Taiwan. The targeted therapeutic population is patients with early-stage Alzheimer's disease, utilizing a botanical new drug compound and a multi-target therapeutic approach to prevent and treat neuropathy.
The company's business plan is mainly divided into three phases. In the short term, active substances are screened through a botanical drug active substance screening platform; on one hand, this can be used for the development and licensing of nutritional supplements and botanical essential oils, and on the other hand, it serves as targets for future new drug development. In the medium term, raw material specifications are standardized through GACP (Good Agricultural and Collection Practice) cultivation base planning technology; on one hand, this allows for the cultivation of B&V BIOPHARMA CO., LTD.'s own medicinal raw material plants, and on the other hand, it can also accept contract cultivation commissioned by other new drug companies. The long-term ultimate goal is the research and development of botanical new drugs, thereby generating milestone payments and sales royalties through the company's drug development.
In its future development, B&V BIOPHARMA CO., LTD. will focus on two areas: botanical new drug research and development, and administrative management. For the subsequent stages of botanical new drug R&D, the company will continue its technical cooperation with the Development Center for Biotechnology; as for administrative management, KPMG is currently providing planning and guidance for internal audits and internal controls, as well as financial and tax auditing services, as the company continues to plan and move toward the goal of an IPO (Initial Public Offering).
The company's business plan is mainly divided into three phases. In the short term, active substances are screened through a botanical drug active substance screening platform; on one hand, this can be used for the development and licensing of nutritional supplements and botanical essential oils, and on the other hand, it serves as targets for future new drug development. In the medium term, raw material specifications are standardized through GACP (Good Agricultural and Collection Practice) cultivation base planning technology; on one hand, this allows for the cultivation of B&V BIOPHARMA CO., LTD.'s own medicinal raw material plants, and on the other hand, it can also accept contract cultivation commissioned by other new drug companies. The long-term ultimate goal is the research and development of botanical new drugs, thereby generating milestone payments and sales royalties through the company's drug development.
In its future development, B&V BIOPHARMA CO., LTD. will focus on two areas: botanical new drug research and development, and administrative management. For the subsequent stages of botanical new drug R&D, the company will continue its technical cooperation with the Development Center for Biotechnology; as for administrative management, KPMG is currently providing planning and guidance for internal audits and internal controls, as well as financial and tax auditing services, as the company continues to plan and move toward the goal of an IPO (Initial Public Offering).
The content above was translated by Ai
